Cardiac Surgery Center, Beijing Anzhen Hospital Affiliated with Capital Medical University, Beijing, China.
Beijing Institute of Heart Lung and Vascular Disease, Beijing Anzhen Hospital Affiliated with Capital Medical University, Beijing, China.
J Thorac Cardiovasc Surg. 2021 Jul;162(1):72-82.e7. doi: 10.1016/j.jtcvs.2020.01.053. Epub 2020 Feb 14.
Whether mitral valve repair is superior to replacement in the population with rheumatic heart disease has been debated. This study aims to compare outcomes of repair with replacement by the propensity score method.
This observational, prospective study enrolled patients with rheumatic heart disease who underwent mitral valve repair and replacement from January 2011 to April 2019. The propensity score method was used to select 2 groups with similar baseline characteristics. Baseline, clinical, and follow-up data were collected. Clinical outcomes included death from any cause, reoperation, and valve-related complications.
The overall population before matching (N = 1644) included 612 patients who underwent repair and 1032 patients who underwent replacement. The propensity score analysis generated matches for 1058 patients (529 pairs). The median follow-up time was 4.12 years. Early mortality and death from any cause during follow-up were significantly lower in the repair group compared with the replacement group (hazard ratio, 0.19; 95% confidence interval [CI], 0.05-0.64; P = .003; hazard ratio, 0.38; 95% CI, 0.19-0.74; P = .003, respectively). Patients in the repair group had a lower risk of valve-related complications compared with patients in the replacement group (subhazard ratio, 0.44; 95% CI, 0.21-0.90; P = .025). In terms of reoperation, no significant difference was observed between the repair and replacement groups (subhazard ratio, 2.54; 95% CI, 0.89-7.22; P = .081).
The results suggest that rheumatic mitral valve repair in select patients is superior to mitral valve replacement with regard to lower mortality and fewer valve-related complications; meanwhile, it has a comparable risk of reoperation compared with replacement.
二尖瓣修复是否优于风湿性心脏病患者的置换一直存在争议。本研究旨在通过倾向评分法比较修复与置换的结果。
这项观察性、前瞻性研究纳入了 2011 年 1 月至 2019 年 4 月期间接受二尖瓣修复和置换的风湿性心脏病患者。采用倾向评分法选择两组基线特征相似的患者。收集基线、临床和随访数据。临床结局包括任何原因导致的死亡、再次手术和瓣膜相关并发症。
在匹配前的总体人群(N=1644)中,有 612 例患者接受了修复术,1032 例患者接受了置换术。倾向评分分析生成了 1058 例患者(529 对)的匹配。中位随访时间为 4.12 年。与置换组相比,修复组的早期死亡率和随访期间的任何原因死亡率均显著降低(风险比,0.19;95%置信区间[CI],0.05-0.64;P=0.003;风险比,0.38;95%CI,0.19-0.74;P=0.003)。修复组患者的瓣膜相关并发症风险低于置换组(亚风险比,0.44;95%CI,0.21-0.90;P=0.025)。在再次手术方面,修复组和置换组之间无显著差异(亚风险比,2.54;95%CI,0.89-7.22;P=0.081)。
结果表明,在选择的患者中,风湿性二尖瓣修复术在降低死亡率和减少瓣膜相关并发症方面优于二尖瓣置换术;同时,其再次手术风险与置换术相当。